JANX-007
JANX-007 is a tumor protease-activated anti-PSMA x CD3 bispecific T cell engager (BiTE). After JANX-007 is cleaved by tumor-specific proteases in the tumor microenvironment to remove the mask, CD3 is exposed, recruiting T cells to kill PSMA-positive tumor cells, and the activated and released TCE fragment can be rapidly cleared. JANX-007 can be used in cancer-related research, such as metastatic castration-resistant prostate cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Species Reactivity
Human
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Target
PSMA & CD3
Conjugated
Unconjugated
Application
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[JANX-007]
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Zhang J, et al. Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies. Cancers. 2024 Sep 06;16(17):3098. [Content Brief]
[2]. Hudson A, et al. A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer. Cancer chemotherapy and pharmacology. 2026 Jan 06;96(1):5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JANX-007 Related Classifications
HY-P992535 Related Classifications
Powered by Bioz